About the Company
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CRSP News
Bullish Trendline Has Never Failed Crispr Therapeutics Stock
Crispr Therapeutics (CRSP) stock is trading within one standard deviation of a historically bullish moving average ...
Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?
CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...
CRISPR Therapeutics' (NASDAQ:CRSP) investors will be pleased with their favorable 63% return over the last five years
It might be of some concern to shareholders to see the CRISPR Therapeutics AG ( NASDAQ:CRSP ) share price down 17% ...
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
CRISPR Therapeutics AG (CRSP) closed at $57.96 in the latest trading session, marking a -1.29% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.03%. Elsewhere, ...
CRISPR Therapeutics AG (CRSP)
ZUG, Switzerland and BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
Buy Rating Affirmed for Crispr Therapeutics AG on Promising Gene Editing Developments and Expanding Treatment Pipeline
Crispr Therapeutics AG (CRSP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on April 1.
CRISPR Therapeutics gets grant for masked car for PTK7 with therapeutic uses
Unlock the potential of targeted therapy with CRISPR Therapeutics AG's patented masked CAR constructs targeting PTK7. Discover the groundbreaking innovation in CAR technology for potential ...
Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics
Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.
CRISPR Therapeutics AG CRSP
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
CRISPR Therapeutics AG CRSP
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...